UBE2L6 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Molibresib (SCHEMBL1872390)	1.00	1/20
Molibresib (SCHEMBL12671490)	1.00	1/20
Molibresib (SCHEMBL12966358)	1.00	1/20
SCHEMBL9998851	0.91	1/20
SCHEMBL14756282	0.88	1/20
SCHEMBL15980874	0.88	1/20
SCHEMBL12966165	0.87	1/20
SCHEMBL14756215	0.87	1/20
SCHEMBL14756339	0.87	1/20
SCHEMBL15980861	0.87	1/20
SCHEMBL9998825	0.86	1/20
SCHEMBL15980893	0.86	1/20
SCHEMBL15980803	0.86	1/20
SCHEMBL1874116	0.85	1/20
SCHEMBL12671221	0.85	1/20
SCHEMBL14756021	0.85	1/20
SCHEMBL14756240	0.85	1/20
SCHEMBL14756287	0.85	1/20
SCHEMBL14756335	0.85	1/20
SCHEMBL14756409	0.85	1/20

Clinical trials — most relevant to UBE2L6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Genistein Aglycone in Glucocorticoid Induced Osteoporosis	PHASE2/PHASE3	UNKNOWN
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study	PHASE3	COMPLETED
A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection	PHASE2	WITHDRAWN
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer	PHASE2	UNKNOWN
Oral Nitrite for Older Heart Failure Patients	PHASE2	COMPLETED
UB-312 in Patients With Synucleinopathies	PHASE1	COMPLETED
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease	EARLY_PHASE1	RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy	nan	COMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS)	nan	UNKNOWN
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)	nan	UNKNOWN
Muscle Wasting in Hemodialysis Patient	nan	COMPLETED
Exploring Novel Biomarkers of ICU-AW in Mechanically Ventilated Children at the Molecular Level	nan	ENROLLING_BY_INVITATION
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas	nan	RECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis	nan	UNKNOWN
Muscle Atrophy In Patients With Chronic Obstructive Pulmonary Disease	nan	UNKNOWN
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Establishment of a Prospective Clinical-biological Database	nan	RECRUITING
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults	nan	COMPLETED
ADAPT: Efficacy of a Dietary Supplement During and After Exercise	nan	COMPLETED
Dysfunctions of Human Muscle Stem Cells in Sepsis	nan	COMPLETED
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS	nan	RECRUITING
Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults	nan	NOT_YET_RECRUITING
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a UBE2L6 binder may also engage these)

Protein	Name	Similarity
A5PJC4	—	0.992	A5PJC4 →
P52487	—	0.991	P52487 →
Q9QZU9	—	0.990	Q9QZU9 →
Q4V8J2	—	0.990	Q4V8J2 →
A0A1B0GUS4	—	0.987	A0A1B0GUS4 →
P63283	—	0.986	P63283 →
Q28CQ4	—	0.986	Q28CQ4 →
P63280	—	0.986	P63280 →
P63281	—	0.986	P63281 →
Q2EF73	—	0.986	Q2EF73 →
P40984	—	0.985	P40984 →
Q21633	—	0.984	Q21633 →
P62253	—	0.984	P62253 →
P35128	—	0.984	P35128 →
UBE2L3	Ubiquitin-conjugating enzyme E2 L3	0.984	landscape →
Q3MHP1	—	0.984	Q3MHP1 →
P61080	—	0.984	P61080 →
P42746	—	0.983	P42746 →
P25866	—	0.983	P25866 →
Q9Z255	—	0.983	Q9Z255 →
Q7ZY08	—	0.983	Q7ZY08 →
Q06AA9	—	0.983	Q06AA9 →
UBE2G2	Ubiquitin-conjugating enzyme E2 G2	0.983	landscape →
Q6Y1Z4	—	0.983	Q6Y1Z4 →
P60605	—	0.983	P60605 →
P62255	—	0.983	P62255 →
P62254	—	0.983	P62254 →
P25153	—	0.983	P25153 →
Q5R4V7	—	0.983	Q5R4V7 →
Q5R5I4	—	0.983	Q5R5I4 →